Entrada Therapeutics, Inc. (TRDA) Income Statement
TRDA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTRDA revenue and net income
Where TRDA's revenue goes
2025Each bar shows an amount and its share of revenue. TRDA kept −565.5% of revenue as net income.
TRDA profit margins
TRDA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −87.9% | +0.2% | — | — |
| Gross profit | −89.9% | — | — | — |
| Operating income | −431.8% | — | — | — |
| Net income | −319.0% | — | — | — |
| EPS (diluted) | −281.2% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TRDA quarterly EPS vs estimates
Entrada Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.98).
TRDA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | $25.3M | $0 | $0 | $0 |
| Cost of revenue | $4.1M | $3.8M | $99.9M | $1.9M | $1.1M | $326,000 | $104,000 |
| Gross profit | $21.3M | $210.8M | $129.0M | −$1.9M | −$1.1M | −$326,000 | −$104,000 |
| Research & development | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M | $21.1M | $8.2M |
| Sales, general & admin | $41.0M | $38.5M | $32.3M | $30.6M | $15.2M | $5.6M | $3.6M |
| Total operating expenses | $177.3M | $163.8M | $132.2M | $97.2M | $51.1M | $26.3M | $11.8M |
| Operating income | −$156.0M | $47.0M | −$3.2M | −$97.2M | −$51.1M | −$26.7M | −$11.8M |
| Interest income | $15.1M | $19.5M | $15.2M | $2.6M | — | $144,000 | $451,000 |
| Interest expense | — | — | — | $2.6M | $31,000 | $0 | $0 |
| Income before taxes | −$142.8M | $66.5M | $12.1M | −$94.6M | −$51.2M | −$26.5M | −$5.1M |
| Income taxes | $924,000 | $859,000 | $18.7M | −$7.2M | −$1.1M | −$144,000 | −$451,000 |
| Net income | −$143.8M | $65.6M | −$6.7M | −$87.5M | −$50.1M | −$26.5M | −$4.6M |
| EBITDA | −$138.7M | $70.3M | $14.9M | −$95.4M | −$50.0M | −$26.2M | −$11.7M |
| EPS (diluted) | −$3.46 | $1.91 | −$0.26 | −$3.02 | −$18.20 | −$12.26 | −$5.18 |
| Gross margin | 83.9% | 100.0% | 100.0% | −7.5% | — | — | — |
| Operating margin | −613.7% | 22.3% | −2.5% | −385.0% | — | — | — |
| Net margin | −565.5% | 31.1% | −5.2% | −346.2% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $898,000 | $875,000 | $1.3M | $1.6M | $1.9M | $20.6M | $37.4M | $19.6M | $94.7M | $59.1M | $41.8M | $43.7M |
| Cost of revenue | $0 | $805,000 | $886,000 | $38.4M | $1.1M | $0 | $992,000 | $900,000 | $900,000 | $934,000 | $736,000 | $22.2M |
| Gross profit | $898,000 | $70,000 | $413,000 | −$36.7M | $1.9M | $20.6M | $37.4M | $19.6M | $94.7M | $59.1M | $41.8M | $21.5M |
| Research & development | $35.4M | $33.1M | $34.0M | $38.4M | $37.9M | $32.1M | $33.4M | $31.3M | $32.0M | $28.6M | $28.3M | $22.2M |
| Sales, general & admin | $10.5M | $10.1M | $9.6M | $10.3M | $10.9M | $10.3M | $9.9M | $10.0M | $9.2M | $9.4M | $8.7M | $7.5M |
| Total operating expenses | $45.9M | $42.4M | $42.6M | $10.3M | $48.8M | $42.3M | $43.3M | $41.2M | $41.3M | $38.0M | $36.9M | $7.5M |
| Operating income | −$45.0M | −$42.3M | −$42.2M | −$47.1M | −$46.8M | −$21.8M | −$5.9M | −$21.7M | $53.4M | $21.1M | $4.9M | $14.0M |
| Interest income | $2.2M | $2.6M | $3.1M | $3.6M | $3.9M | $4.4M | $5.1M | $5.8M | $4.4M | $4.2M | $4.3M | $4.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $4.4M | — |
| Income before taxes | −$42.7M | −$39.7M | −$39.1M | −$43.5M | −$42.9M | −$17.3M | −$739,000 | −$15.9M | $57.8M | $25.3M | $9.2M | $52.9M |
| Income taxes | $35,000 | $38,000 | $92,000 | $654,000 | $178,000 | — | −$1.9M | −$1.9M | $2.8M | $1.8M | $18.7M | $17.4M |
| Net income | −$42.8M | −$39.7M | −$39.2M | −$44.1M | −$43.1M | −$17.3M | $1.1M | −$14.0M | $55.0M | $23.5M | −$9.5M | $35.5M |
| EBITDA | −$41.9M | −$38.9M | −$41.9M | −$42.2M | −$41.9M | −$16.4M | $253,000 | −$15.0M | $58.7M | $26.3M | $9.9M | $53.7M |
| EPS (diluted) | −$1.01 | −$0.95 | −$0.94 | −$1.06 | −$1.04 | −$0.42 | $0.03 | −$0.35 | $1.55 | $0.68 | −$0.29 | $1.02 |
| Gross margin | 100.0% | 8.0% | 31.8% | −2,276.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 49.3% |
| Operating margin | −5,007.0% | −4,834.6% | −3,249.3% | −2,915.2% | −2,402.5% | −106.0% | −15.7% | −110.7% | 56.4% | 35.7% | 11.7% | 32.0% |
| Net margin | −4,762.0% | −4,539.1% | −3,014.9% | −2,734.4% | −2,210.4% | −84.4% | 3.0% | −71.7% | 58.1% | 39.7% | −22.8% | 81.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TRDA's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TRDA financial results
In fiscal year 2025 (ended December 31, 2025), Entrada Therapeutics reported revenue of $25.4 million, down 87.9% from the year before. It had a net loss of $143.8 million, a net profit margin of −565.5%. Diluted earnings per share came to −$3.46.
See the TRDA stock overview for the latest quote and news, or the TRDA chart for price history and technical indicators.
TRDA income statement FAQ
What is Entrada Therapeutics's annual revenue?
Entrada Therapeutics reported total revenue of $25.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 87.9% from $210.8 million the previous year.
Is Entrada Therapeutics profitable?
No. Entrada Therapeutics reported a net loss of $143.8 million in fiscal 2025, a net profit margin of −565.5%; its operating margin was −613.7%.
What is Entrada Therapeutics's gross margin?
Entrada Therapeutics's gross margin was 83.9% in fiscal 2025: for every $100 of revenue, Entrada Therapeutics kept $84 after the direct cost of its products and services.
How much does Entrada Therapeutics spend on research and development?
Entrada Therapeutics spent $142.3 million on research and development in fiscal 2025, 559.7% of revenue.
What are Entrada Therapeutics's earnings per share?
Entrada Therapeutics earned $-3.46 per diluted share in fiscal 2025, compared with $1.91 a year earlier.
When will Entrada Therapeutics report its next earnings?
Entrada Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Entrada Therapeutics's fiscal year end?
Entrada Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.